Phase 2 S-1 Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2
Allo HSCT Using RIC and PTCy for Hematological Diseases
Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 2
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
FruquintinibS-1Raltitrexed
Meng Qiu66 enrolled2 locationsNCT06427005
Completed
Phase 2
An open-label study of the safety and efficacy of 12 weeks treatment with BIT225 and Combination Antiretroviral Therapy (cART) in patients with Human Immunodeficiency Virus-1 (HIV-1) with only partial immune reconstitution.
Human Immunodeficiency Virus-1 infection
Biotron Limited20 enrolled3 locationsACTRN12621001354875
Completed
Phase 2
A study of the safety and efficacy of 6 months treatment with BIT225 and Combination Antiretroviral Therapy (cART) in patients with Human Immunodeficiency Virus-1 (HIV-1) compared to cART alone, including measurement of BIT225 in the blood, antiviral activity and immune markers.
Human Immunodeficiency Virus-1 infection
Biotron Limited27 enrolled1 locationACTRN12621000937819
Completed
Phase 2
A study of the safety of 3 months treatment with BIT225 and Combination Antiretroviral Therapy (cART), in patients with Human Immunodeficiency Virus-1 (HIV-1), compared to cART alone, including measurement of the concentration of BIT225 in the blood and antiviral activity.
Human Immunodeficiency Virus-1 infection
Biotron Limited36 enrolled1 locationACTRN12617000025336
Completed
Phase 2
A study of the safety of BIT225 in combination with pegylated interferon and ribavirin in patients with hepatitis C virus and human immunodeficiency virus co-infection, who are naive to treatment with pegylated interferon and ribavirin, and whose HIV is currently well controlled by standard antiretroviral therapy.
Hepatitis C Virus infection in patients co-infected with human immunodeficiency virus-1
Biotron Limited12 enrolled1 locationACTRN12612001189819